The ShiftShapers Podcast
Change either paralyzes or energizes - the choice is yours. Hear from businesses and entrepreneurs who have become energized and who have profited by shaping the shifts in their markets and practices. Become a SHIFTSHAPERS INSIDER and get our latest download, advance notice of all podcasts, podcast summaries, and special INSIDER-ONLY content. INSIDER SIGN UP
The ShiftShapers Podcast
Ep# 360: Taming "The Other" Claims Cost Monster - with Surya Singh
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
This week’s episode features a conversation with Surya Singh, CEO and Co-founder at gWell. Muskoskeletal claims are growing monster that gobbles up claims spends. Cutting-edge tech in genomics, AI, and machine learning help create diagnostics for the best treatments since many chronic conditions have genetic markers associated with them. At the same time, this technology cuts costs by as much as a third of current spends, a significant percentage that's of interest to employers and patients alike.
What You’ll Learn From This Episode:
- 01:57 Surya’s professional background
- 03:44 Musculoskeletal claims: Rising costs associated with longer lives
- 06:14 Genomics and genetics help diagnose chronic conditions
- 13:46 AI and machine learning accurately determine the recovery time of patients
- 18:46 Genetic testing and genomics cut overall spend by a third
Quotes:
05:06 “People are surviving longer and so after you get that first knee surgery, arthroscopic knee procedure, even a knee replacement or hip replacement, you may outlive it. You may live long enough that you need another one now.”
08:41 “For almost every common chronic disease or condition that develops, there are multiple genes at play. And not only are there multiple genes at play, those genes are expressed, they are used, in different combinations and at different levels by the body.”
15:39 “We can understand which of those pathways are the ones that are leading to better form and function, leading to better phenotypic outcomes for people. Artificial intelligence and machine learning are a way to be able to do that.”
18:22 “Which genetic markers that dictate whether or not they respond well to e-centric exercise, the weight-bearing exercise, and how long their recovery periods are in between can really help dictate are they out from being functional again for 2 weeks or a month or 6 months.”
20:30 “One thing I worry about in terms of making sure that the impact is as broad as it can be in terms of economics and in terms of value, and also to use another little cliche that’s used a lot now, that no one is left behind so to speak.”
There's another claims cost monster that isn't pharma, but it's been eating huge chunks of plan budgets. What is it? And what brand new techniques are being used to tame it? We'll find out on this episode of Shift Shapers.
AnnouncerChange either paralyzes or energizes. The choice is yours. You're listening to the Shift Shapers podcast. You're about to learn firsthand from businesses and entrepreneurs who have successfully shaped the shifts in their industries. Get ready to become the change you want to see. This episode is brought to you by Shift Shaper Strategies. In sales, if you confuse, you lose. Clarify your message so you win more clients, crush your sales goals, and build your practice. Learn more at ShiftShaperStrategies.com. And now, here's your host, Storybrand Certified Guide and Chief Transformation Strategist at Shift Shaper Strategies, David Staltzman.
DavidYou know, as anybody who's looked at medical spend knows, especially recently, musculoskeletal claims are a humongous part of overall medical spend. And sometimes it's kind of hard to think about like who's doing anything about that. And the good news is that there are some folks who are looking at that and looking at different modalities and different ways of tackling the problem to try to bring some sense into the picture and to try to bring some economies of scale. They're using things like genomics, AI, clinically informed personalization, and microsegmentation. Now, I don't even know what some of those things mean, but by the end of the podcast, we will. And that's why we invited our guest today, Surya Singh, who's CEO and co-founder of GWEL. Surya, welcome. Thank you for having me. It's my pleasure to be here. Thanks so much. Now, you're a physician and an entrepreneur. What kind of was the progress that brought you to this particular segment of the industry?
SPEAKER_01So it goes back a couple of steps in my career. And as you mentioned, I'm a physician and have had a long-standing interest in, I would say, the behavior of the human body from a very kind of uh cellular and molecular level. That's what I originally studied and was very interested in genetics from an intellectual and research standpoint. But I spent a lot of my career really focused on the cost of care and the value of health care that's delivered, particularly from the managed care vantage point. I spent seven years as the chief medical officer of the specialty pharmacy at CVS to that end. But another thread in addition to thinking about value and cost, and then genetics and genomics and epigenetics, which we'll talk about, is this idea that if we can empower individuals, if we can get people not just to feel accountable for their own health and wellness, but to feel like they can do something to help themselves feel and function better, that that is really kind of part of the, you know, the secret sauce, if you will, to helping people achieve better outcomes. And we often hide it under this word of engagement. We're creating a new program and we want to go engage the individual and engage the patient. And I see it more as, and what really led me to what I'm doing now and what we do at GWIL as empowerment, that individuals can be empowered. Individuals are capable of being able to understand, raise their own level of understanding, and achieve more for themselves in order to both feel and function better.
DavidSo that's the personalization and micro-segmentation that you were talking about? Absolutely. Let's level set. How big a part of claim spend is musculoskeletal, and and what kinds of claims do we see and what kinds of dollars are we spending?
SPEAKER_01So musculoskeletal is incredibly large as a portion of healthcare spend. So depending on the specific population that we're looking at, and obviously some demographics, what the age is and so on of that particular population on average will have an influence, but it's somewhere between 16 and 25 percent in the different uh series of claims that we've looked at. So it rivals very closely other things that we think about as big chunks of healthcare. Therapeutics or pharmacy, for instance, where I spent a big chunk of my career, it is another one that's right around the same level as spend. Musculoskeletal, however, is driven largely by procedures and interventions. And I think if you total it all up, there's an organization that's really a consortium of a bunch of different member organizations called the U.S. Bone and Joint Initiative that has the best data on this. Their figure for overall musculoskeletal spend in the U.S. is about $950 billion with a B. So it's an incredibly expensive part of our healthcare spend and one that continues to grow. And why is it growing? Well, it's growing because population's aging, as we all know. People are surviving longer. And so after you get that first knee surgery, arthroscopic knee procedure, even a knee replacement or hip replacement, you may outlive it. You may live long enough that you need another one now, where that wasn't the case in the past. And then there's a lot of innovation in the actual types and the breadth of procedures that we can do. And so as that, you know, sort of number and different type of procedures grows, and there's innovation in that field as well, we do more. There's more utilization because we're actually, you know, sort of driving down to people who have lower levels of acuity in their injury or the condition that's being modified or treated. And so there's more procedures being done early and earlier. And when you combine that with what I was talking about in terms of longevity, now you have really kind of this growing spend in a procedurally driven field.
DavidSo what you're trying to accomplish is not necessarily looking at hip replacements, but looking at David's hip replacement. Correct. So we've talked about when we've talked to pharmacy guys, we've talked, and you're an old pharmacy hand, we've talked about pharmacogenetic testing. You mentioned genomics, which is kind of in that same ballpark. How does that help you get down from hip replacements to David's hip replacement? And why do you do that?
SPEAKER_01Yeah, that's a fantastic question. It's also kind of fundamental to how we think about things. So I'm going to take a step back uh for a second. I will definitely come back to the hip replacement and actually the, you know, a little bit of the factors and the biology, the biologic factors that lead to you needing that hip replacement. But if you take it, if you zoom out and open up the aperture for a second on you know what's happening with this field overall, and you mentioned pharmacogenomics, which I've spent a fair amount of time thinking about and analyzing over the years, that runs across. But there are there are basically three chunks of what people think about when they think about uh genetics and genomics on the diagnostic side. On the therapeutic side, which I won't talk about as much today, there's a lot of interest that I have a lot of personal interest in cellular and gene therapy approaches. But let's focus on the testing part of this. So we think about in genomics and genetics monogenic testing. So, you know, cystic fibrosis is an example, diseases, Huntington's disease, familiar hypocholesterolemia, things where there's a specific gene that's been identified, we have an assay for it, we test, you get a diagnosis. That's one chunk of this field. Another chunk that people think about a lot and gets a lot of attention and research funding, rightfully, is tumor genomics. So cancer obviously is fundamentally often a genetic disease, and so the study of that and and being able to understand what all the different combinations and mutations mean for people's cancer genetics is really important. That's the second area. And I sometimes bucket separately, although I'll do it as kind of a 2B here. People hear about genetics a lot in the prenatal testing space, obviously, because we use chromosomes in particular, and then genetics in particular there. So it's another place that we we think about. But the third area is the one that we're really focused on that I'm going to talk about most today, and then I'll use this segue back to the hip replacement example. And that's polygenic assessment of risk and response for common chronic conditions and polygenic, you know, the word, so multiple genes. So looking at multiple different sites within the DNA. And for almost every common chronic disease or you know, condition that develops, there are multiple genes at play. And not only are there multiple genes at play, those genes are expressed, they are used in different combinations and at different levels by the body in response to what's happening in its environment. And this is the old nature and nurture question. And we often think, okay, it's genetic, so it's part of nature. Nurture is not only, you know, what did you eat and how did you exercise today? It's, you know, sort of all the components of your environment, including what is the hormonal balance that you have, not because of, you know, menopause only or you know, those sorts of factors. It's fight or flight, how much adrenaline, how much epinephrine is in your body, which genes are being turned on as a result of that, for how long is that being perpetuated? What does that do fundamentally to the on-switch for that gene? And a lot of people think about in this space inflammation, which starts to bring me back to the hip replacement example and back to musculoskeletal or bone joint muscle problems. But just to close out on the genomic description, those sorts of conditions that are in my third bucket where we're really kind of thinking about the combination of different genes, that's where we are focused and focused specifically on musculoskeletal conditions that affect bones, muscles, and joints. And then to bring it back to the hip replacement example, there are a bunch of genes that have already been validated and specific markers, variants within them as being important in the development of both osteoarthritis and in osteoporosis. And so osteoporosis, remember, well, people I think know what arthritis is in osteoarthritis of getting to bone on bone and not having cartilage in between and then anymore and degradation of the of the actual bone surface, where the bone actually needs to be resurfaced and often replaced, as we're talking about in hip replacement, whether it's partial or full. And then osteoporosis. So one stat that we talk about internally at the company a lot as we're doing our work related to this point around hip replacements and hip fractures is that over the age of 65, about 50% of Americans have a hip fracture. So it's a staggering figure. So, you know, a lot of people end up needing an intervention because of that hip fracture that they sustain. And then of that group who get the procedure, about a quarter and sometimes a little more than a quarter are dead within 12 months of their procedure. So it's often the inciting event that leads people to this downward spiral that we really want to try to help prevent. So back to the question of David's hip replacement versus an overall hip replacement, if you have different factors, genetic factors, that are invariants that are at play with respect to both development and then the severity of osteoarthritis and to bone density problems, how we think about A, the type of intervention that may be best for you, where should they actually attach the hip replacement? That's something that could be influenced in the future by this, by this science. But very tactically, for an individual, how do you work to prevent the muscle atrophy that will lead you to have a much longer recovery period? So even in the pre-surgical phase, if it's an elective procedure and not the result of a hip of a hip fracture, or B, if many years ahead of time you know that you're at risk from a genetic standpoint of having osteoarthritis and or osteoporosis, we seek to guide you to take different steps and make different lifestyle choices to try to minimize that that risk, whether it's vitamin D supplementation, whether it's different types of exercises, with a totally different lens on the motivation for doing those things.
AnnouncerAnd now, a word from our sponsor. It's a fact. Salespeople and organizations lose opportunities because they don't clearly communicate their value. In today's market, your story is your message. It should be crystal clear, perfectly arranged, and precisely targeted to attract the clients you want. As a certified story brand guide, we use the exclusive SB7 process to create that story and the websites and collateral that deliver it. If your message isn't cutting through the noise, we can help.com to learn how we can help you find, clarify, and deliver a message that wins clients and approaches sales goals and builds your practice. In sales, if you confuse, you lose. So learn more and schedule that call today at ShiftShaperstrategies.com. That's shiftshapersstrategies.com. And now back to our discussion.
DavidNow you're also using AI and maybe some machine learning in your process. We talked a lot because obviously there's a lot of curiosity around AI or the broad field that's usually captioned as AI. How does that help in the process of what you guys are trying to achieve?
SPEAKER_01So another, you know, sort of important part of this field and of you know sort of trying to figure out, because as you as you can imagine, again, like take artificial intelligence, AI and and ML, but machine learning, as tools in the toolkit instead of as a you know, sort of uh just as as they get used a lot and I think in the industry right now as buzzwords and and ways to describe this very, you know, it's black box. But just we like to think of them as ways to be able to help navigate this vast array of different pathways that can be taken as you try to get somebody from point A to point B in terms of precision, health, and wellness. And so if you take, you know, sort of back to that example, if we just stick with the example of osteoarthritis and osteoporosis and say there are thousands of different combinations of the validated markers that we know right now. And each individual can have any combination of those. Well, now we have a team of experts assembled to be able to say, here's dozens or hundreds of different combinations of those thousands that are highly relevant. So let's distill it down. We still need to do this phenotypic annotation, and that's another, you know, sort of wonky way to describe. But let's take the form and function that different groups of people have, individuals assembled into groups, and map them to that. Now, what I just said were dozens or hundreds of genetic signatures related to osteoarthritis and osteoporosis or broadly musculoskeletal. And through that mapping, we can understand which of those pathways are the ones that are leading to better form and function, leading to better phenotypic outcomes for people. Artificial intelligence and machine learning are a way to be able to do that, that allows the system to be able to understand better which of those paths are the ones that are really highlighted and are leading people to have better outcomes and better performance over time.
DavidWell, you touched on this briefly a little while ago. I'd like to kind of circle back a little bit about the importance of giving patients tools and understanding. When you were talking about, you know, if you knew that you were predisposed to certain things at a younger age, different courses could be taken so that you don't end up with being the David with the hip replacement. How important is that as part of your long-term project and also as part of day-to-day patient management?
SPEAKER_01So it's very important. So the follow-up of patients and being able to understand how individuals are doing in many fields is important. But in musculoskeletal, because pain in particular is such an important component of this and disability or decreased function, which is why I think in the self-funded employer universe, this is such an important topic because people lose their ability to be able to not just work, be able to function fundamentally, both because of the pain and because of the associated disability. And the two aren't always coupled, but often are. But the patient-reported outcomes, which is kind of the moniker for it, you know, PROs are incredibly important to musculoskeletal and being able to track those over time and understand now, after the follow-up period, you know, whether it's a month in some cases or whether it's 12 months in other cases, whether the outcome that we're seeing persists and whether the person has really improved and been able to have sustained improvement is incredibly important, both to you know, the outcome to ROI, to all of the things that we really want to be able to try to drive and understand over time, that follow-up and understanding what happens to people after that more precise or personalized intervention was put in place is really important. And it does dovetail back to this idea of it's not the health event, whether it's an injury or as we've been talking about, a surgery. But, you know, just to use a different example, if someone is active and they're lifting weights and they hurt their lower back, or they're working in a warehouse and they hurt their lower back, how they recover from that injury can be very different based on what different techniques and what different therapeutic approaches are used. And I don't just mean injections or a spinal fusion. I mean physical therapy, exercises, and whether or not a tailored program that really takes into account, for instance, which genetic markers they have that dictate whether or not they respond well to eccentric exercise, to weight-bearing exercise, and how long their recovery periods are in between can really help dictate, you know, are they out essentially from being functional again for two weeks or a month or six months?
DavidBroad question, but you know, it's the question everybody always asks when you get down to the end of the conversation, which is what kind of an impact can the work that you're doing, or do you hope the work you're doing will make on unit cost or overall spend?
SPEAKER_01So I think if you take everything that we're doing and employ it and put it in place for a population, and that applies to all parts of that Pareto analysis of that pyramid, you know, the people that already have an acute problem, acute on chronic pain, people who have chronic pain, people who are trying, who are active or you know, have an active job where they're they're often lifting heavy objects or they're active in the as a weekend warrior or whatever the case might be, and put them in the preventive bucket, you apply it to all of them. Well, our analysis of musculoskeletal claims says that we can save about a third of overall spending in musculoskeletal. So I think that the effect can be profound, but you know, that that obviously has a series of assumptions baked into it. But that look, I mean, this field is one where a lot of the innovation, as I mentioned, you know, early on, has been in better interventions, which is important. But prevention, as we all know, to use the old adage, is worth an ounce of cure. And maybe the ratio is even as you know, prevention, sorry, an ounce of prevention is worth a pound of cure. But you know, if you say it's one to 16, I think it's probably better than one to 16 in this case, in some specific areas in terms of health and wellness, when you combine the overall just core economics with the quality of life, with the other part of the value equation, if you take, you know, sort of outcomes over cost. But you know, the other thing I'll say on that, on that point of return is that, you know, this connects back to the individual empowerment idea. This is a field where, and I just you know talked about in terms of the pyramid, but I would say just more broadly, if I one one thing I worry about in terms of making sure that the impact is as broad as it can be in terms of economics and in terms of value, but also that, and it to use another little uh cliche that's used a lot now, that no one is left behind, so to speak. A lot of the analysis that's been done and a lot of the work that's been done in this field so far, not talking about musculoskeletal genomics and even at the intersection of those two and genomics in general, has been very available to those who can afford it, not only the ultra-wealthy, but the wealthy. It's been very Eurocentric. And so we we're we're a little bit hamstrung by some of the consequences of that now. We don't have a broad and diverse population from which the research is drawn, and we need to shift that. And that's another part of what we we aim to do is broaden access and make sure that that fundamental flaw is rectified before this field gets too mature because it will have huge and outsized downstream consequences if we're not careful.
DavidWell, that's a great place to end our conversation, but we do hope you'll come back. This is this is fascinating. Surya Singh, CEO and co-founder of GWE. Surya, thanks for taking time to talk to our audience today. Thanks so much, David. It's been my privilege.
AnnouncerThe Shift Shapers Podcast is a production of Shift Shaper strategies and may not be reproduced or quoted in whole or in part without our express written permission. Copyright 2020, all rights reserved.